- Prothena to participate in February investor healthcare conferences, February 24-25
DUBLIN, Ireland, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that it will report its fourth quarter and full year 2013 financial results on Thursday, March 6, 2014, after the close of the U.S. financial markets. The announcement will be followed by a conference call and live audio webcast at 4:30 p.m. ET.
The conference call and live audio webcast can be accessed as follows:
Dial-in: (877) 887-5215 (U.S. toll free) or (315) 625-3069 (international)
Conference ID Number: 88110742
Webcast: http://ir.prothena.com
A replay of the webcast will be available until March 14 via dial-in to (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 88110742, or via webcast on the investor relations section of Prothena's website at http://ir.prothena.com.
Upcoming Investor Healthcare Conferences
Members of the management team will present and/or participate in one-on-one investor meetings at these upcoming investor healthcare conferences:
- Citi's 2014 Global Healthcare Conference on Monday, February 24 at the Hilton New York Hotel
- 2014 RBC Capital Markets' Global Healthcare Conference on Tuesday, February 25 at 10:00 a.m. ET at the New York Palace Hotel
A live webcast of the RBC Capital Markets' presentation can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion. These potential therapies have a number of indications, including AL and AA forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002), and novel cell adhesion targets involved in inflammatory diseases and metastatic cancers (PRX003). For more information, please visit www.prothena.com.